Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated has announced its participation in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference scheduled for June 14, 2023. The event aims to showcase the company's mission of transforming the lives of patients dealing with serious and rare diseases. Insmed's first commercial product has been approved in major markets for a chronic lung disease, and the company continues to develop therapies for unmet medical needs. The chat will be accessible via a live webcast from the company's investor relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is actively presenting at notable healthcare conferences, enhancing its visibility.
  • The company is committed to addressing serious and rare diseases, indicating a strong mission.
  • Insmed has a robust pipeline of investigational therapies targeting unmet medical needs.

Full Press Release Details

BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA , on Wednesday, June 14, 2023 at 1:20 p.m. PT ( 4:20 p.m. ET ).
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When will Insmed present at the Goldman Sachs Conference?

Insmed will present on June 14, 2023, at 1:20 p.m. PT.

How can I access the Insmed fireside chat webcast?

The webcast will be available on Insmed's investor relations page.

What is Insmed's mission?

Insmed aims to transform the lives of patients with serious, rare diseases.

Where is Insmed Incorporated headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

What does Insmed's pipeline target?

Insmed's pipeline targets serious unmet needs in inflammatory and pulmonary disorders.

Last updated: Jun 7, 2023